Head to Head Analysis: Collegium Pharmaceutical (COLL) vs. Its Rivals

Collegium Pharmaceutical (NASDAQ:COLL) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Collegium Pharmaceutical to similar businesses based on the strength of its profitability, earnings, institutional ownership, risk, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for Collegium Pharmaceutical and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	1	1	6	1	2.78
Collegium Pharmaceutical Competitors	7750	13840	25681	1031	2.41

Collegium Pharmaceutical currently has a consensus target price of $48.71, suggesting a potential upside of 102.81%. As a group, “Pharmaceuticals” companies have a potential upside of 24.05%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than its rivals.

Profitability

This table compares Collegium Pharmaceutical and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Collegium Pharmaceutical Competitors	-2,380.63%	-221.06%	-16.01%

Valuation and Earnings

This table compares Collegium Pharmaceutical and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Collegium Pharmaceutical	$808.21 million	$62.87 million	19.37
Collegium Pharmaceutical Competitors	$3.55 billion	$3.19 billion	546.79

Collegium Pharmaceutical’s rivals have higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical’s rivals have a beta of -4.34, indicating that their average stock price is 534% less volatile than the S&P 500.

Institutional and Insider Ownership

32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.8% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats its rivals on 8 of the 13 factors compared.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.